IBEX 35
10.710,10 -54,90 (-0,51%) Euro Stoxx 50
4.924,94 -11,63 (-0,24%) Dólar/Euro
1,0667 +0,0020 (+0,19%) Petróleo Brent
86,67 -0,44 (-0,51%) Oro
2.396,10 -1,90 (-0,08%) Bitcoin EUR
60.772,57 +2.389,60 (+4,09%)
Neurogenesis, Inc. (NEUN)
Neurogenesis, Inc.
1241 Butler Road
League City, TX 77573
United States
281 557 7877
https://www.neurogenesis.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Albert H. Bieser | Chairman, Chief Executive Officer and President | 36k | N/A | 1934 |
| Dr. Terry Neher | Chairman of Advisory Board, Chief Clinical Advisor, VP - Research & Development and Director | 27,05k | N/A | 1941 |
| Ms. Karen Coady | Controller | N/A | N/A | N/A |
Descripción
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.
Gobierno corporativo
El ISS Governance QualityScore de Neurogenesis, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
